Network 1 Tech | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.02.

EBIT: As of FY2025 Q3, the actual value is USD -1.267 M.

Segment Revenue

• Revenue for the nine months ended September 30, 2025, was $150,000, compared to $100,000 for the same period in 2024, all from litigation settlements involving the Remote Power Patent.

Operational Metrics

• Operating expenses for the three months ended September 30, 2025, were $800,000, compared to $896,000 for the same period in 2024, primarily due to decreased professional fees and general administrative expenses.
• Operating expenses for the nine months ended September 30, 2025, were $2,315,000, compared to $2,538,000 for the same period in 2024, with decreases in professional fees and general administrative expenses.
• Net loss for the three months ended September 30, 2025, was $560,000, compared to $316,000 for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $1,386,000, compared to $1,894,000 for the same period in 2024.

Cash Flow

• Net cash used in operating activities for the nine months ended September 30, 2025, was $606,000, compared to $685,000 for the same period in 2024.
• Net cash used in investing activities for the nine months ended September 30, 2025, was $2,241,000, compared to cash provided by investing activities of $1,614,000 for the same period in 2024.
• Net cash used in financing activities for the nine months ended September 30, 2025, was $2,590,000, compared to $3,510,000 for the same period in 2024.

Unique Metrics

• The company recorded realized and unrealized gains on marketable securities of $215,000 for the nine months ended September 30, 2025, compared to $395,000 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue its licensing efforts and monetization of its patent portfolios, focusing on acquiring high-quality patents with significant licensing opportunities.
• Non-Core Business: The company has invested $7,000,000 in ILiAD Biotechnologies, LLC, a clinical-stage biotechnology company, and continues to evaluate strategic opportunities.
• Priority: The company emphasizes the importance of successfully monetizing its patent portfolios and achieving a return on its investment in ILiAD to positively impact its business and financial condition.